Immunotherapy for bladder cancer: rediscovering an old friend

BJU Int. 2016 May;117(5):721-4. doi: 10.1111/bju.13330. Epub 2015 Oct 20.

Authors

Mark Voskoboynik^{1

2}, Sarah Rudman¹, Hendrik-Tobias Arkenau^{2

3}, Simon Hughes¹, Simon Chowdhury^{1

2}

Affiliations

¹ Department of Medical Oncology, Guy's Hospital, London, UK.
² Sarah Cannon Research Institute UK, London, UK.
³ University College London, London, UK.

PMID: 26389688
DOI: 10.1111/bju.13330

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / therapeutic use
B7-H1 Antigen / antagonists & inhibitors
BCG Vaccine / therapeutic use
CTLA-4 Antigen / antagonists & inhibitors
Humans
Immunologic Factors / therapeutic use
Immunotherapy*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Urinary Bladder Neoplasms / therapy*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
B7-H1 Antigen
BCG Vaccine
CTLA-4 Antigen
Immunologic Factors
PDCD1 protein, human
Programmed Cell Death 1 Receptor